retatrutide type 2 diabetes phase 2 results 2024 2025 Positive Top-line for in Diabetes: TRANSCEND-T2D-1 π¨Breaking: Retatrutide's first Phase 3
Description
Starting July 2026, a short-term program called the Medicare GLP-1 Bridge, designed as a bridge to the broader BALANCE model, will cover Wegovy, Zepbound and Foundayo for eligible Part D enrollees at a $50 monthly copayment
most have demonstrated the action only in cocaine and alcohol abuse [94,95]
Int J Neurosci Khvatova EM et al
It is currently being evaluated in clinical trials
